Skip to main content
SpringerLink
Log in

Alisertib/gemcitabine

Various toxicities: 6 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Chen JA, et al. A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer. Cancer Chemotherapy and Pharmacology 90: 217-228, No. 3, Sep 2022. Available from: URL: http://doi.org/10.1007/s00280-022-04457-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alisertib/gemcitabine. Reactions Weekly 1935, 26 (2022). https://doi.org/10.1007/s40278-022-28821-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-28821-6

Search

Navigation